Related Experiment Videos
Advances in diabetes technology: clinical implications, limitations, and future perspectives
Maria Apostolopoulou1,2, Grigorios Effraimidis3,4
1Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. maria-apostolopoulou@hotmail.com.
Hormones (Athens, Greece)
|June 12, 2026
Summary
Diabetes technology like continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems have revolutionized diabetes care. These advancements offer significant benefits but still face challenges, with future innovations focusing on personalization and AI integration.
Area of Science:
- Endocrinology and Metabolic Diseases
- Biomedical Engineering
- Digital Health
Background:
- Diabetes management has been transformed by technological advancements over the last two decades.
- Continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems are central to modern diabetes care, especially for type 1 diabetes (T1D).
- CGM offers continuous insights into glucose trends and variability, often replacing traditional self-monitoring of blood glucose.
Purpose of the Study:
- To review the evolution of diabetes technologies, focusing on CGM and insulin delivery systems.
- To summarize evidence on the application of these technologies in various clinical contexts.
- To explore emerging developments and future directions in diabetes technology.
Main Methods:
- Narrative review of randomized controlled trials and real-world studies.
- Analysis of evidence on the evolution of CGM technology and insulin delivery strategies.
- Exploration of technological applications in specific clinical settings.
Main Results:
- CGM and AID systems provide significant metabolic and psychosocial benefits for individuals with diabetes.
- Limitations include delayed insulin pharmacokinetics, sensor lag, and user-dependent factors.
- Emerging technologies include fully closed-loop systems, dual-hormone systems, and AI for data analysis.
Conclusions:
- Diabetes technology has significantly improved glycemic control and quality of life.
- Addressing current limitations is crucial for further advancements.
- Future research should focus on personalization, technology integration, and predictive/proactive care using AI.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...